Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurogene (NGNE) Payables (2018 - 2025)

Historic Payables for Neurogene (NGNE) over the last 6 years, with Q3 2025 value amounting to $1.5 million.

  • Neurogene's Payables fell 831.35% to $1.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.5 million, marking a year-over-year decrease of 831.35%. This contributed to the annual value of $1.3 million for FY2024, which is 4853.62% down from last year.
  • Neurogene's Payables amounted to $1.5 million in Q3 2025, which was down 831.35% from $2.1 million recorded in Q2 2025.
  • In the past 5 years, Neurogene's Payables ranged from a high of $5.4 million in Q1 2023 and a low of $1.3 million during Q4 2024
  • In the last 3 years, Neurogene's Payables had a median value of $2.1 million in 2025 and averaged $2.5 million.
  • Its Payables has fluctuated over the past 5 years, first tumbled by 7192.4% in 2024, then skyrocketed by 10124.84% in 2025.
  • Neurogene's Payables (Quarter) stood at $2.6 million in 2023, then tumbled by 48.54% to $1.3 million in 2024, then rose by 15.57% to $1.5 million in 2025.
  • Its Payables was $1.5 million in Q3 2025, compared to $2.1 million in Q2 2025 and $3.1 million in Q1 2025.